Self-Study 2025 Release I: Treatment of Non-Melanoma Skin Cancers

Type: Individual•Format: On-demand

Non-melanoma skin cancers (NMSC) are a heterogeneous group of cutaneous cancers consisting of basal cell carcinoma, cutaneous squamous cell carcinoma, and Merkel cell carcinoma. NMSCs are the most common type of skin cancer, and their incidence rates are continuing to rise globally. Treatment of NMSCs often consists of a multidisciplinary approach, including surgery and radiation; in patients with locally advanced or metastatic disease, or who are not surgical candidates, systemic therapy is indicated. The purpose of this course is to review treatment options in the management of non-melanoma skin cancers. This will include a review of the role of immunotherapy and hedgehog pathway inhibitors at different stages, and will include efficacy and safety data, as well as considerations for patient monitoring and toxicity management.

Treatment of Non-Melanoma Skin Cancers

UAN#: 0465-0000-25-067-H01-P

Author: Christine Barrett, PharmD, BCOP

Learning Objectives

  1. Summarize the efficacy data for immunotherapy in non-melanoma skin cancers
  2. Review the safety data for hedgehog pathway inhibitors in basal cell carcinoma
  3. Develop strategies for toxicity management of hedgehog pathway inhibitors

Get it here

Knowledge Course for Pharmacists

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.